<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04253106</url>
  </required_header>
  <id_info>
    <org_study_id>APHP190483</org_study_id>
    <nct_id>NCT04253106</nct_id>
  </id_info>
  <brief_title>Liquid Biopsies for the Personalized Management of Patients With Hereditary Diffuse Gastric Cancer</brief_title>
  <acronym>LISA-HDGC</acronym>
  <official_title>Liquid Biopsies (Blood, Gastric Fluid) for the Personalized Management of Patients With Hereditary Diffuse Gastric Cancer: a Pilot Project</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Activating somatic mutations and methylation profiles identified by liquid biopsies could&#xD;
      identify CDH1 and CTNNA1 pathogenic variants carriers with invasive diffuse gastric cancer&#xD;
      undetectable by upper G-I endoscopy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Carriers of germline pathogenic variants in the CDH1 and CTNNA1 genes have the Hereditary&#xD;
      Diffuse Gastric Cancer Syndrome. Asymptomatic carriers have at high lifetime risk of diffuse&#xD;
      gastric cancer (30-70%). Screening upper gastrointestinal endoscopy, even with multiple&#xD;
      random biopsies, misses signet ring cell cancer foci. Invasive cancers can thus go&#xD;
      undetected. There is therefore a recommendation of total risk-reducing gastrectomy, at least&#xD;
      in carriers with a family history of gastric cancer. Novel screening strategies are needed.&#xD;
      In this pilot project, the investigators will perform liquid biopsies of both blood and&#xD;
      gastric fluid in asymptomatic carriers who refuse gastrectomy and in controls. The&#xD;
      investigators aim to show that somatic mutations in a panel of genes involved in gastric&#xD;
      cancer and methylation profiles are detected in a subset of carriers, and not in controls.&#xD;
      These could be indicative of invasive cancer undetected by endoscopy, and would thus be a&#xD;
      strong argument for risk-reducing gastrectomy. On the contrary, in the absence of somatic&#xD;
      mutations in liquid biopsies, endoscopic surveillance could continue.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 26, 2020</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicentric, prospective non-randomized study prognostic aim. Control group planned to have standard values.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects in whom somatic mutations or methylation profiles are detected.</measure>
    <time_frame>Over two years of surveillance</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Replicability of observations over successive endoscopies. Correlation between blood and gastric fluid.</measure>
    <time_frame>Over two years of surveillance</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Hereditary Diffuse Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Unaffected carriers of constitutional mutations</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with CDH1 or CTNNA1 germline pathogenic variant. No history of diffuse gastric cancer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>All patients with FOGD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>without observation of macroscopic lesions paired with cases (age and sex)</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Liquid biopsies (blood, gastric fluid).</intervention_name>
    <description>Next generation sequencing of a panel of diffuse gastric cancer genes, methylation analysis. Samples collected during routine screening endoscopy.</description>
    <arm_group_label>All patients with FOGD</arm_group_label>
    <arm_group_label>Unaffected carriers of constitutional mutations</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Case:&#xD;
&#xD;
          -  Patient&gt;18 years old&#xD;
&#xD;
          -  CDH1 or CTNNA1 germline pathogenic variant.&#xD;
&#xD;
          -  No history of diffuse gastric cancer.&#xD;
&#xD;
          -  French social security.&#xD;
&#xD;
          -  Ability to understand and willingness to sign a written informed consent document.&#xD;
&#xD;
        Volunteers:&#xD;
&#xD;
          -  Patients &gt; 18years old&#xD;
&#xD;
          -  Patients with no oncological history&#xD;
&#xD;
        Exclusion Criteria: for both arms&#xD;
&#xD;
          -  Patients with cancer being treated&#xD;
&#xD;
          -  Patients with metastatic cancer&#xD;
&#xD;
          -  Medical contraindication to general anesthesia or FOGD (bleeding disorder, pregnant&#xD;
             women )&#xD;
&#xD;
          -  Patients under guardianship or curator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>BENUSIGLIO Patrick, MD PhD</last_name>
    <phone>33142177659</phone>
    <email>patrick.benusiglio@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hopital Pitié Salpetrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Benusiglio, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>January 31, 2020</study_first_submitted>
  <study_first_submitted_qc>January 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>November 30, 2020</last_update_submitted>
  <last_update_submitted_qc>November 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data entry and management under the responsibility of Dr Patrick Benusiglio investigator coordinating the study</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

